![US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents](https://patentimages.storage.googleapis.com/53/e6/c8/ddb746dfbf35a4/US20030064097A1-20030403-D00003.png)
US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents
![US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents](https://patentimages.storage.googleapis.com/8b/5a/69/f6132b03ed1810/US20030064097A1-20030403-D00001.png)
US20030064097A1 - Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions - Google Patents
![Alia Vitaminum b1 in iunctione cum vitamino b6 et/vel b1| Potassium-iron(iii)-phosphate-citrate-complex| Acidum acetylsali-cylicum| Mediator autem activae eget pharmaceutical ingredients et praecursores - 90 Alia Vitaminum b1 in iunctione cum vitamino b6 et/vel b1| Potassium-iron(iii)-phosphate-citrate-complex| Acidum acetylsali-cylicum| Mediator autem activae eget pharmaceutical ingredients et praecursores - 90](https://image.goldpharma.com/articles_400x400/DE04847302.jpg)
Alia Vitaminum b1 in iunctione cum vitamino b6 et/vel b1| Potassium-iron(iii)-phosphate-citrate-complex| Acidum acetylsali-cylicum| Mediator autem activae eget pharmaceutical ingredients et praecursores - 90
![PDF) 0372 Arousability of Insomnia Patients is Not Impacted by the Orexin Antagonist Suvorexant (10 mg and 20 mg) PDF) 0372 Arousability of Insomnia Patients is Not Impacted by the Orexin Antagonist Suvorexant (10 mg and 20 mg)](https://i1.rgstatic.net/publication/332405179_0372_Arousability_of_Insomnia_Patients_is_Not_Impacted_by_the_Orexin_Antagonist_Suvorexant_10_mg_and_20_mg/links/5d8df7c0458515202b6d6ac8/largepreview.png)